Melanoma patients with BRAF mutation usually have a positive response to treatment with BRAF inhibitors, but nearly all of those patients develop resistance to the drugs and experience disease progression.
Now, a new preclinical study published online ahead of print in the â‰ˆ
from Penn Medicine researchers found that in many cases the root of the resistance may lie in a never-before-seen autophagy mechanism induced by the BRAF inhibitors vermurafenib and dabrafenib. Autophagy is a process by which cancer cells recycle essential building blocks to fuel further growth. Block this pathway with the antimalarial drug hydroxycholoroquine (HCQ), the authors found, and the BRAF inhibitors will be able to do their job better.
"This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven''t been explored deeply as a therapeutic option for patients whose tumors are resistant," said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology/Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center. "Here, we show that the BRAF inhibitors induce autophagy as a way to escape cell death, which gives us clues on how to interfere with this mechanism of resistance and improve outcomes for these patients."
Based on these promising preclinical results, Dr. Amaravadi and his team have already launched a clinical trial for patients with advanced BRAF mutant melanoma to see how well-tolerated HCQ is with the BRAF inhibitor vemurafenib. "So far," he said, "we are seeing a benefit to patients and low toxicity."
BRAF inhibitors are a first line of treatment for melanoma patients who harbor the BRAF mutation, which is an abnormal change in a gene that causes some melanoma tumors to grow and spread more aggressively. While 50 percent of patients initially respond to that treatment, nearly 100 percent exhibit disease progression seven months after treatment, making it imperative to find a way to re-sensitize the tumor to treatment.
Autophagy has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation; however, autophagy as a potential druggable mechanism in patients who become resistant to BRAF inhibitors has not been investigated.
Using tumor biopsies from BRAF melanoma patients treated with either BRAF inhibitors or with combined BRAF and MEK inhibitors, a recently FDA-approved drug combination to fight the other mechanisms of resistance, the researchers found that tumors resistant to the BRAF inhibitors had increased levels of autophagy compared with baseline tumors. Moreover, the level of therapy-induced autophagy was correlated with lower response rates and shorter progression-free survival times.
The researchers also examined BRAF mutant melanoma cell lines, and found that BRAF inhibition induced autophagy by way of an endoplasmic reticulum (ER) stress response. The binding of a BRAF mutation to the ER stress gatekeeper GRP78 is a new and unexpected molecular interaction driving resistance, and establishes a new signaling axis that has multiple drug targets, Dr. Amaravadi said.
What''s more, the researchers found that blocking this mechanism with HCQ--a drug used to treat malaria that has been shown in previous studies to block autophagy--limited BRAF inhibitor-induced autophagy and enhanced cancer cell death in mouse models.
"As the use of BRAF inhibitors become more widespread, we''ll need to discover new options for our patients so they can overcome this destined resistance," said Dr. Amaravadi. "Here, we have a new pathway that links the BRAF mutation to ER stress and autophagy that could be exploited with an already-approved FDA drug, which I believe could be a game changer for this group of patients."
Next steps are to continue to enroll patients in the clinical trial investigating autophagy inhibitors in combination with BRAF inhibitors and potentially other, emerging new drug combinations proven to improve patient response.
Other Penn authors include Xiao-Hong Ma, Sheng-Fu Piao, Quentin Mcafee, Giorgos Karakousis, Lori S. Hart, Samuel Levi, Janice Hu, Xiaowei Xu, Wei Xu, Lynn M. Schuchter, Jeffrey Winkler, Constantinos Koumenis; Jessie Villaneuva, Gao Zhang, and Meenhard Harlyn from the Wistar Institute; Rossitza Lazova and Vincent Klump from Yale University; and Michael A. Davies from MD Anderson Cancer Center.
This study was supported by National Institutes of Health grants K23CA120862, P01CA114046 and 1R01CA139362.
: Inquiries for the clinical trial (a phase I trial of vemurafenib and hydroxychloroquine for patients with BRAF mutant melanoma; clinicaltrials.gov: NCT01897116) may be directed to Victoria Baldassarre 215-662-7615.
Penn Medicine is one of the world''s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation''s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report''s survey of research-oriented medical schools. The School is consistently among the nation''s top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System''s patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation''s top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation''s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.